Acorda Therapeutics
Founded Year
1995Stage
Loan | IPOTotal Raised
$144.54MMarket Cap
0.02BStock Price
15.62About Acorda Therapeutics
Acorda Therapeutics, a biotechnology company, is developing therapies for spinal cord injury (SCI and related neurological conditions, including multiple sclerosis (MS. The Companyƒ-s lead product, Fampridine-SR, is in Phase 3 clinical trials for chronic SCI and Phase 2 for MS. Acordaƒ-s technology platform includes two remyelinating agents in preclinical development for MS. They include M1, a class of human monoclonal antibodies, and GGF2, a product of the neuregulin 1 gene. Both agents have been shown to restore myelin in the brain and spinal cord in animal models of MS. Additionally, Acorda is developing multiple approaches to regeneration and repair of the spinal cord and brain. In 2002, Acorda was the recipient of the National Spinal Cord Injury Associationƒ-s L. W. Freeman Award for scientific research. Nasdaq: ACOR
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Acorda Therapeutics Patents
Acorda Therapeutics has filed 160 patents.
The 3 most popular patent topics include:
- Calcium channel blockers
- Potassium channel blockers
- Neurological disorders
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
9/9/2019 | 2/1/2022 | Transcription factors, Tyrosine kinase receptors, Clusters of differentiation, Cardiac arrhythmia, Proteins | Grant |
Application Date | 9/9/2019 |
|---|---|
Grant Date | 2/1/2022 |
Title | |
Related Topics | Transcription factors, Tyrosine kinase receptors, Clusters of differentiation, Cardiac arrhythmia, Proteins |
Status | Grant |
Latest Acorda Therapeutics News
Aug 8, 2023
Views: 1 By Hannah Albarazi (August 7, 2023, 10:33 PM EDT) — A New York federal judge has confirmed a nearly $16.6 million arbitral award issued to Acorda Therapeutics Inc. in its dispute with Alkermes PLC over a multiple sclerosis drug, but refused to increase the award by $65.6 million to refund the company for royalties paid after the drug’s patent expired….
Acorda Therapeutics Frequently Asked Questions (FAQ)
When was Acorda Therapeutics founded?
Acorda Therapeutics was founded in 1995.
Where is Acorda Therapeutics's headquarters?
Acorda Therapeutics's headquarters is located at 420 Saw Mill River Road, Ardsley.
What is Acorda Therapeutics's latest funding round?
Acorda Therapeutics's latest funding round is Loan.
How much did Acorda Therapeutics raise?
Acorda Therapeutics raised a total of $144.54M.
Who are the investors of Acorda Therapeutics?
Investors of Acorda Therapeutics include Paycheck Protection Program, J.P. Morgan Chase & Co., LBi International, Highbridge Capital Management, BAM Elevate and 38 more.
Who are Acorda Therapeutics's competitors?
Competitors of Acorda Therapeutics include Bicycle Therapeutics, NellOne Therapeutics, Eiger BioPharmaceuticals, FirstString Research, Synapsin Pharmaceuticals, Merus, Syndax Pharmaceuticals, Hyperion Therapeutics, iPierian, RetroScreen Virology and 15 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Acorda Therapeutics to Competitors
Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.
OcuNexus Therapeutics is a development stage biopharmaceutical company that develops treatments for front- and back-of-the-eye diseases and disorders.
CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.
Juventas Therapeutics, formerly AcelleRx Therapeutics, Juventas Therapeutics is a privately held, clinical stage biotechnology company focused on developing non-viral gene therapies to treat advanced cardiovascular diseases. The Company's lead product candidate, JVS-100, is a non-viral gene therapy undergoing evaluation in clinical studies for the treatment of advanced cardiovascular diseases.
Lead Pharma is a spinoff from the Hubrecht Institute and the University Medical Center Utrecht, developing innovative small-molecule therapies for patients with autoimmune disease or cancer.
Nanotope is a regenerative medicine company that leverages a core set of technologies to address multiple therapeutic markets. Nanotope is developing a suite of products, each customized to regenerate specific tissues; including neuronal, vascular, bone, myocardial, and cartilage. The products are injectable compounds that work with surviving cells in and around the point of damage to initiate and support tissue regeneration and growth. Once regeneration is complete, the compounds are safely broken down and removed by the body. Nanotope's lead products target neuron regeneration for prevention or reversal of paralysis associated with spinal cord injury and angiogenesis for wound healing and the treatment of peripheral artery disease.n
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
